InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP

BEIJING, Feb. 08, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application to conduct clinical trials […]


1 M.
Technology
ID: 2906092020193746620


Similar News expand_more


Technology
Science
Travel
Science
Technology
Science
Technology
Science
Technology
Science
Science
Science
Economics
Technology
Science
Education
Science
Science
Technology
Crime
Science
Education
Science
Technology
Technology
Technology
Technology
Science
Science
Real Estate
Technology
Science
Technology
Politics
Education
Technology
Technology
Technology
Technology
Technology
Science
Science
Science
Technology
Science
Science
Science
Science
Education
Add Watch Country

arrow_drop_down